C₂₅H₂₄N₆O₂ (P274)
Quantities
| P2067 | mass | 440.196 |
| P3780 | active ingredient in | ... | Q29005968 (Imbruvica) | Imbruvica |
| P233 | canonical SMILES | String | C=CC(=O)N1CCCC(C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N | ??? |
| P373 | Commons category | String | Ibrutinib | ??? |
| P527 | has part(s) | ... | Q623 (carbon) | carbon |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2017 | isomeric SMILES | String | C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N | ??? |
| P8026 | LiverTox likelihood score | ... | Q83284515 (LiverTox toxicity likelihood category D) | LiverTox toxicity likelihood category D |
| P2175 | medical condition treated | ... | Q29496 (leukemia) | leukemia |
| P2175 | medical condition treated | ... | Q268713 (mantle cell lymphoma) | mantle cell lymphoma |
| P2175 | medical condition treated | ... | Q136312 (central nervous system lymphoma) | central nervous system lymphoma |
| P2175 | medical condition treated | ... | Q208414 (lymphoma) | lymphoma |
| P2175 | medical condition treated | ... | Q1088156 (chronic lymphocytic leukemia) | chronic lymphocytic leukemia |
| P2175 | medical condition treated | ... | Q1138590 (non-Hodgkin lymphoma) | non-Hodgkin lymphoma |
| P2175 | medical condition treated | ... | Q1194520 (graft-versus-host disease) | graft-versus-host disease |
| P2175 | medical condition treated | ... | Q1778287 (Waldenström macroglobulinemia) | Waldenström macroglobulinemia |
| P2175 | medical condition treated | ... | Q2626074 (diffuse large B-cell lymphoma) | diffuse large B-cell lymphoma |
| P2175 | medical condition treated | ... | Q4833719 (B-cell lymphoma) | B-cell lymphoma |
| P2175 | medical condition treated | ... | Q18553852 (lymphoblastic leukemia) | lymphoblastic leukemia |
| P129 | physically interacts with | ... | Q401536 (BLK proto-oncogene, Src family tyrosine kinase) | BLK proto-oncogene, Src family tyrosine kinase |
| P129 | physically interacts with | ... | Q423572 (Bruton's tyrosine kinase) | Bruton's tyrosine kinase |
| P129 | physically interacts with | ... | Q21106693 (BMX non-receptor tyrosine kinase) | BMX non-receptor tyrosine kinase |
| P3489 | pregnancy category | ... | Q28123618 (US pregnancy category D) | US pregnancy category D |
| P769 | significant drug interaction | ... | Q18216 (aspirin) | aspirin |
| P769 | significant drug interaction | ... | Q307088 (abciximab) | abciximab |
| P769 | significant drug interaction | ... | Q410237 (clopidogrel) | clopidogrel |
| P769 | significant drug interaction | ... | Q304088 (acenocoumarol) | acenocoumarol |
| P769 | significant drug interaction | ... | Q177094 (imatinib) | imatinib |
| P769 | significant drug interaction | ... | Q414462 (apixaban) | apixaban |
| P769 | significant drug interaction | ... | Q415366 (tirofiban) | tirofiban |
| P769 | significant drug interaction | ... | Q416232 (prasugrel) | prasugrel |
| P769 | significant drug interaction | ... | Q420262 (rivaroxaban) | rivaroxaban |
| P769 | significant drug interaction | ... | Q420542 (ticagrelor) | ticagrelor |
| P769 | significant drug interaction | ... | Q2295855 (eptifibatide) | eptifibatide |
| P769 | significant drug interaction | ... | Q5186964 (crizotinib) | crizotinib |
| P769 | significant drug interaction | ... | Q5908266 (idelalisib) | idelalisib |
| P769 | significant drug interaction | ... | Q113368879 (rac-warfarin) | rac-warfarin |
| P279 | subclass of | ... | Q27163257 (1-[3-[4-amino-3-(4-phenoxyphenyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinyl]-2-propen-1-one) | 1-[3-[4-amino-3-(4-phenoxyphenyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinyl]-2-propen-1-one |
| P2868 | subject has role | ... | Q7251487 (protein kinase inhibitors) | protein kinase inhibitors |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | ibrutinib | ??? |
Why not click here or view trends?
log id: 2755398